Turn your smartphone in portrait mode
to properly consult our website, thank you!
Vidence powers a cancer-free future, enabling the development of new treatments
for patients through data-driven, evidence-based analytics and insights.
Vidence harnesses the power of clinical and genomic data and insights to advance the treatment and outcomes for oncology patients.
A healthcare informatics company, Vidence provides the world’s leading cancer researchers, innovators and treatment providers with the ability to contribute to and access the most comprehensive knowledge base of patient journeys and outcomes.
Vidence Consortium Fellows are leading healthcare systems, independent hospitals, and cancer clinics that share a strong commitment and passion for improving the treatment journey for cancer patients.
They recognize the value of data-driven insights in the care and treatment of their own patients as well as the importance of informing and accelerating the development of new drugs, treatment regimens, protocols and clinical research.
Vidence Consortium Fellows contribute their data to the Vidence technology platform, SCIMON, in return for the ability to analyze and visualize their own data in a rich structure environment, leveraging tools to provide insights that inform and can improve their ability to effectively treat their oncology patients.
Want To Learn More? Get In Touch
The value and quality of Vidence’s oncology data, services
and technology are unparalleled in the industry
patient journeys and growing through the Consortium
patient reported outcomes
patients with detailed genomic sequencing
SCIMON is Vidence’s proprietary technology platform that brings together data and analytics in one patient-centric knowledge repository.
SCIMON holds clinical, genetic/genomic, claims, and operational data in both structured and unstructured formats.
Utilizing advanced technology including artificial intelligence (AI), machine learning (ML) and natural language processing (NLP), SCIMON aggregates, analyzes and organizes the data from disparate sources and formats and provides tools to enable users to extract business intelligence, conduct healthcare economics and outcomes research (HEOR) studies and visualize critical data.
Utilizing the SCIMON platform, the Vidence team can conduct bespoke analyses
Identification and analysis of market trends in every area of oncology, including, but not limited to, diagnostics, treatment, outcomes, claims and operations
Understanding the effectiveness of therapies, care and patient outcomes for specific disease or patient populations
Observing patient treatment trends, quality of life (QOL), patient reported outcomes (PRO), and living patient journeys
Analysis of frequency and effectiveness of products or treatment regimens in specific disease states
Cost/benefit analysis of rebates/incentives for products, treatments or services for specific disease or patient segments
Vidence helps companies harness the power of big data through visualized dashboards and reports.
Enables users to quickly filter and visualize large datasets using metrics, key performance indicators (KPIs), and other important data points for data analysis
Observe population studies of cancer and cancer-related outcomes
Uncover patterns and trends in datasets, enable better collaboration and speed up the decision-making process
Connect securely and available from anywhere, anytime
In addition to data analysis, Vidence’s professional tools and services can help accelerate active product and drug development, clinical studies and treatment planning.
A variety of services to enhance and accelerate clinical trial matching, recruitment and design
To track, visualize and utilize precision medicine testing results at the point of care
Quality measurement tools to gauge performance and compliance with government regulations and certification programs
Identify and analyze patient cohorts for clinical insights and optimization of treatment and outcomes
Vidence has selected the 2bPrecise™ platform, a precision medicine data delivery solution, to make it easier for its Consortium Fellows to unlock the true power of genomic data at the point of care and facilitate the advancement of precision oncology. Vidence’s proprietary SCIMON™ technology platform will seamlessly integrate with the 2bPrecise cloud-based platform delivering data-driven insights directly into the provider’s workflow to prompt an evidence-based choice of action.
Vidence and NTT DATA Services, a global digital business and IT services leader, today announced a relationship to build advanced AI and ML algorithms to predict patient outcomes, enhance decision-making, and drive clinical trials to advance cancer research and treatment. This unique collaboration will utilize a combination of medical imaging scan, clinical and outcomes data to build a predictive model that will optimize treatment regimens.
Vidence, LLC, an oncology informatics company, was officially launched today as an independent entity to provide the world’s leading cancer researchers, innovators and providers with the most comprehensive clinical and genomic data and insights. Founded by leading members of the medical and technical communities, Vidence fills an evidence gap in oncology and helps pharmaceutical and biotech firms and other healthcare institutions accelerate the development of cancer treatments and optimize patient care.